# A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients

> **NCT02304315** · PHASE2 · COMPLETED · sponsor: **Green Cross Corporation** · enrollment: 40 (actual)

## Conditions studied

- Hepatitis B Infection

## Interventions

- **BIOLOGICAL:** GC1102 50,000 IU
- **BIOLOGICAL:** GC1102 80,000 IU

## Key facts

- **NCT ID:** NCT02304315
- **Lead sponsor:** Green Cross Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2016-06-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02304315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02304315, "A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02304315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*